Table 5 MetaCore pathway analysis of differentially expressed genes of the treatment comparison IN versus OUT.
Day 5 IN vs OUT | P-value | Significant* | Total** |
|---|---|---|---|
Transcription_Ligand-Dependent Transcription of Retinoid-Target genes | 0.00022 | 7 | 32 |
G-protein signalling_G-Protein alpha-s signalling cascades | 0.00473 | 5 | 28 |
Transcription_CREM signalling in testis | 0.00626 | 4 | 19 |
Proteolysis_Putative ubiquitin pathway | 0.01076 | 4 | 22 |
Immune response_PGE2 signalling in immune response | 0.01102 | 5 | 34 |
Development_Lipoxin inhibitory action on PDGF, EGF and LTD4 signalling | 0.01468 | 4 | 24 |
Inhibitory action of Lipoxin A4 on PDGF, EGF and LTD4 signalling | 0.01468 | 4 | 24 |
Cell cycle_Initiation of mitosis | 0.01694 | 4 | 25 |
Cell cycle_Regulation of G1/S transition (part 1) | 0.01748 | 5 | 38 |
Muscle contraction_GPCRs in the regulation of smooth muscle tone | 0.02082 | 6 | 54 |
Day 28 IN vs OUT | P -value | Significant* | Total** |
Cytoskeleton remodeling_CDC42 in cellular processes | 0.00013 | 7 | 22 |
Oxidative stress_Role of ASK1 under oxidative stress | 0.00013 | 7 | 22 |
Immune response_Histamine H1 receptor signalling in immune response | 0.00028 | 9 | 40 |
Development_VEGF signalling and activation | 0.00044 | 8 | 34 |
Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling | 0.00079 | 15 | 107 |
Cytoskeleton remodeling_Cytoskeleton remodeling | 0.00079 | 14 | 96 |
Immune response_IL-3 activation and signalling pathway | 0.00108 | 7 | 30 |
Immune response_Histamine signalling in dendritic cells | 0.00118 | 8 | 39 |
Development_TGF-beta receptor signalling | 0.00135 | 9 | 49 |
Signal transduction_Activation of PKC via G-Protein coupled receptor | 0.00267 | 8 | 44 |
Day 56 IN vs OUT | P -value | Significant* | Total** |
Peroxisomal branched chain fatty acid oxidation | 0.00004 | 8 | 22 |
Cholesterol Biosynthesis | 0.00024 | 7 | 21 |
Neurophysiological process_Dopamine D2 receptor transactivation of PDGFR in CNS | 0.00068 | 6 | 18 |
Propionate metabolism p.1 | 0.00196 | 5 | 15 |
Development_Angiotensin signalling via beta-Arrestin | 0.00281 | 6 | 23 |
G-protein signalling_G-Protein alpha-12 signalling pathway | 0.00448 | 7 | 33 |
Delta508-CFTR traffic/ER-to-Golgi in CF | 0.00783 | 4 | 13 |
G-protein signalling_Rap2B regulation pathway | 0.00783 | 3 | 7 |
Development_Mu-type opioid receptor signalling via Beta-arrestin | 0.00962 | 5 | 21 |
Mitochondrial unsaturated fatty acid beta-oxidation | 0.01709 | 4 | 16 |